Abstract
LSD1 (KDM1A; BHC110; AOF2) was the first protein reported to exhibit histone demethylase activity and has since been shown to have multiple essential roles in mammalian biology. Given its enzymatic activity and its high-level expression in many human malignancies, a significant recent focus has been the development of pharmacologic inhibitors. Here we summarize structural and biochemical knowledge of this important epigenetic regulator, with a particular emphasis on the functional and preclinical studies in oncology that have provided justification for the evaluation of tranylcypromine derivative LSD1 inhibitors in early phase clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 1103-16 |
| Number of pages | 14 |
| Journal | Epigenomics |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Journal Article
Research Highlights, Institutes and Platforms
- Manchester Cancer Research Centre
Fingerprint
Dive into the research topics of 'LSD1: biologic roles and therapeutic targeting'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver